All In Biotech

Drug Trial Radar · NCT07681271

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 30, 2026

Primary completion

Dec 7, 2027

Study completion Dec 7, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

Conditions

  • Papulopustular Rosacea

Interventions

  • LOU064Drug

    LOU064 administered by oral route

  • PlaceboDrug

    Matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change from baseline in facial inflammatory lesion countTime frame: Baseline, Week 16

Locations

17 sites in 9 countries. Site status is shown where the registry gives one.

  • Three A Research

    El Paso, Texas · Recruiting

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    Sofia, Bulgaria · Recruiting

  • Novartis Investigative Site

    London, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Markham, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Shanghai, China · Recruiting

  • Novartis Investigative Site

    Guangzhou, Guangdong, China · Recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Recruiting

  • Novartis Investigative Site

    Tübingen, Germany · Recruiting

  • Novartis Investigative Site

    Cona, FE, Italy · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Singapore, Singapore · Recruiting

  • Novartis Investigative Site

    Icheon, South Korea · Recruiting

  • Novartis Investigative Site

    Dongjak Gu, Seoul, South Korea · Recruiting

  • Novartis Investigative Site

    Córdoba, Spain · Recruiting

  • Novartis Investigative Site

    Granada, Spain · Recruiting

  • Novartis Investigative Site

    Santiago de Compostela, A Coruna, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.